Diversified Trust Co Sells 2,680 Shares of IDEXX Laboratories, Inc. $IDXX

Diversified Trust Co cut its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 63.8% in the first quarter, Holdings Channel.com reports. The firm owned 1,519 shares of the company’s stock after selling 2,680 shares during the quarter. Diversified Trust Co’s holdings in IDEXX Laboratories were worth $854,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the company. SHP Wealth Management purchased a new stake in IDEXX Laboratories in the 4th quarter worth about $26,000. Virtus Advisers LLC purchased a new position in shares of IDEXX Laboratories during the third quarter valued at approximately $26,000. Park Place Capital Corp purchased a new position in shares of IDEXX Laboratories during the fourth quarter valued at approximately $29,000. WealthCollab LLC bought a new position in shares of IDEXX Laboratories during the second quarter valued at approximately $30,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in shares of IDEXX Laboratories during the third quarter valued at approximately $36,000. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Stock Up 1.5%

Shares of IDEXX Laboratories stock opened at $549.16 on Thursday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The stock has a market cap of $43.32 billion, a price-to-earnings ratio of 40.44, a PEG ratio of 2.96 and a beta of 1.55. The firm’s 50-day moving average is $559.95 and its two-hundred day moving average is $616.34. IDEXX Laboratories, Inc. has a 1 year low of $506.91 and a 1 year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the previous year, the business posted $2.91 EPS. The company’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Wall Street Zen raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Stifel Nicolaus reduced their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Citigroup began coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price for the company. Finally, UBS Group lowered their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.